Oxikodon Depot Actavis (Oxycodone Hydrochloride)

Oxikodon Depot Actavis is an opioid analgesic indicated for several pain‑related conditions within the chronic pain management pathway.

• Cancer‑related pain: Provides sustained relief for patients with malignant disease experiencing persistent pain.
• Post‑surgical pain: Offers prolonged analgesia following major surgical procedures.
• Severe chronic non‑cancer pain: Delivers continuous opioid coverage for conditions such as severe osteoarthritis or neuropathic pain unresponsive to other therapies.

• Oxycodone Hydrochloride acts as a full agonist at the μ‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces neuronal excitability, and decreases the transmission of nociceptive signals, resulting in analgesia.

Adverse reactions to Oxikodon Depot Actavis can vary in frequency and severity.

Common Side Effects

• Constipation: Reduced gastrointestinal motility leading to hard stools.
• Nausea: Sensation of queasiness often accompanied by an upset stomach.
• Drowsiness: Generalized sedation or feeling of tiredness.
• Dry mouth: Decreased salivary secretion causing a parched oral cavity.
• Dizziness: Light‑headed sensation, especially when standing quickly.
• Itching: Mild pruritus without rash.

Serious or Rare Side Effects

• Respiratory depression: Markedly slowed breathing that can be life‑threatening.
• Severe hypotension: Significant drop in blood pressure leading to fainting.
• Opioid use disorder: Development of physical dependence and addiction.
• Seizures: Uncontrolled electrical activity in the brain.
• Anaphylaxis: Acute, potentially fatal allergic reaction.
• adrenal ​      ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

When prescribing Oxikodon Depot Actavis, clinicians should consider several safety measures.

• Assess patient history: Review          ...  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 
• Monitor  …  … … … … … … … ... … … … ... … … … … … … … … … … … … … … … …
• Avoid  …  … ... … … … … … … … … … … … … … … … … … …
• Adjust dose for renal or hepatic impairment:  ...  …  … … … … … … …
• Educate patients on signs  … 
• Store at below 25°C: keep in the original pack, protect from moisture.

• Oxikodon  ​       …   …  …  …  ...    …  … …  … ...  ...